BTG2 and hepatocellular carcinoma: Due to METTL3-mediated m6A modification, LncMEG3 expression is downregulated, its inhibitory effect on miR-544b is weakened, and the decreased expression of BTG2 promotes the progression of hepatocellular carcinoma (HCC)56.